Withania somnifera — commonly known as ashwagandha, Indian ginseng, or winter cherry — is a medicinal herb central to Ayurvedic medicine for over 3,000 years. Its primary traditional applications are as a rasayana (rejuvenating tonic) for stress, fatigue, cognitive function, and reproductive health. The active constituents are primarily withanolides — steroidal lactones concentrated in the root — along with alkaloids and sitoindosides.
Ashwagandha is classified as an adaptogen: a substance that helps the body adapt to physical and psychological stressors. It is one of the most commercially successful adaptogens globally, with the Irish and UK market seeing significant growth. Products in Irish health stores typically use one of two proprietary standardised extracts: KSM-66® (Ixoreal Biomed) or Sensoril® (Natreon Inc.).
KSM-66® is a root-only extract standardised to ≥5% withanolides, produced using a cold extraction process that preserves the natural withanoside profile of the whole root. It has the most extensive clinical research base of any ashwagandha extract, with over 22 published human clinical trials. KSM-66 is considered the gold standard for ashwagandha research.
Sensoril® is a root and leaf extract, standardised to ≥10% withanolides and ≥32% oligosaccharides. The higher withanolide content means lower doses can be used (typically 125–250 mg vs 300–600 mg for KSM-66). Sensoril has its own clinical research portfolio, particularly in stress, sleep, and cognitive function.
The practical difference is minor for most users: both are high-quality, well-researched proprietary extracts significantly superior to generic, unstandardised ashwagandha root powder. When a product doesn't specify KSM-66 or Sensoril, it is likely a generic extract with less certainty around bioactive content.
The most frequently cited KSM-66 trial is the 2012 double-blind, randomised, placebo-controlled study by Chandrasekhar et al., published in the Indian Journal of Psychological Medicine. This trial enrolled 64 adults with a history of chronic stress and randomised them to 300 mg KSM-66 twice daily (600 mg total) or placebo for 60 days. Primary outcomes were serum cortisol levels, self-reported stress (Perceived Stress Scale), and anxiety (Hamilton Anxiety Rating Scale).
Results showed statistically significant reductions in serum cortisol (27.9% reduction vs 7.9% placebo), PSS stress scores, HAMA anxiety scores, and improvements in the serum DHEA-S:cortisol ratio. All improvements were significantly greater in the ashwagandha group. This is a well-designed, peer-reviewed RCT and represents genuine clinical evidence for cortisol modulation.
A 2019 RCT by Langade et al. (published in Cureus, n=60) found that KSM-66 300 mg twice daily for 10 weeks significantly improved total sleep time, sleep efficiency, morning alertness, and mental alertness compared to placebo. The sleep benefits aligned with reduced anxiety scores, suggesting the mechanism may be primarily anxiolytic rather than directly soporific.
Multiple RCTs with KSM-66 have examined male testosterone levels, muscle strength, and body composition. Wankhede et al. (2015) found significant improvements in muscle strength and testosterone in resistance-trained men taking 300 mg KSM-66 twice daily over eight weeks. Mahdi et al. (2009) found improved semen quality and testosterone in men with infertility. These are modest-size trials but from credible peer-reviewed sources.
| Claim | Evidence Level | Source |
|---|---|---|
| Reduces serum cortisol in chronic stress | Strong | Chandrasekhar et al. 2012 RCT (n=64, double-blind) |
| Improves sleep quality and duration | Moderate | Langade et al. 2019 RCT (n=60) |
| Reduces anxiety (HAM-A score) | Moderate | Multiple RCTs; Chandrasekhar 2012; Pratte et al. 2014 |
| Improves testosterone and muscle strength | Moderate | Wankhede et al. 2015 RCT (male participants) |
| Replaces antidepressant or anxiolytic medication | No Evidence | Not studied as pharmaceutical replacement; not comparable |
KSM-66 is typically dosed at 300 mg twice daily (morning and evening with food) for stress, anxiety, and cortisol support. Some protocols use 600 mg once daily. Sensoril is typically used at 125–250 mg once or twice daily. Effects are generally noticeable after 4–8 weeks of consistent use.
Taking ashwagandha with warm milk or a fat-containing meal is suggested in Ayurvedic tradition and may enhance absorption of the lipophilic withanolides.
Standard guidance is to cycle ashwagandha — use for 8–12 weeks, then take a 4–8 week break. Long-term continuous use data beyond 12 months is limited.
Ashwagandha has a generally good short-term safety record at standard doses. The most common side effects are GI disturbance (nausea, loose stool) and, rarely, headache. These are more common at higher doses.
Thyroid interaction — important for Irish users. Ashwagandha can stimulate thyroid hormone production. Several studies have documented increased T3 and T4 levels with ashwagandha supplementation (Gannon et al. 2014, Panda & Kar 1998). For people with hypothyroidism on levothyroxine, this can lead to unpredictable fluctuation in thyroid hormone levels, potentially causing hyperthyroid symptoms (palpitations, anxiety, insomnia, weight loss). Conversely, for someone with subclinical hypothyroidism, the thyroid-stimulating effect may be beneficial. Anyone on thyroid medication must discuss ashwagandha with their GP and get thyroid function monitored if starting supplementation.
Ashwagandha has mild sedative properties. Additive effects with sedating medications (benzodiazepines, antihistamines, sleep aids) are possible. It may also have mild immunostimulant effects — caution in autoimmune conditions and following organ transplant (immunosuppressant interaction risk).
Ashwagandha, specifically KSM-66, has some of the best RCT evidence in the adaptogen category. The cortisol and stress data are genuine and the sleep research is credible. It is not a replacement for pharmaceutical treatment of anxiety disorders, depression, or thyroid conditions. The thyroid interaction is a real safety issue that is frequently underplayed in supplement marketing — anyone with thyroid disease or on thyroid medication should get medical advice before starting. For otherwise healthy adults under significant stress, ashwagandha KSM-66 at standard doses is a reasonable, evidence-supported choice.